You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)認購Anwita優先股合作研發治療藥
阿思達克 06-25 05:27

君實生物(01877.HK)公布,認購Anwita 299萬股優先股,佔其發行在外股份20%,現金代價1,000萬美元。Anwita專注於創新蛋白質工程,以生成用於免疫腫瘤學(IO)的同類最優細胞因子。

同時,雙方訂立許可協議,於大中華區開發及商業化Anwita的創新IL-21融合蛋白AWT008。完成AWT008技術轉讓後,公司須支付現金200萬美元。此外,若AWT008符合提交IND的要求,公司可批准繼續提交IND並進行隨後的臨床試驗以就其商業銷售獲得監管許可。因此,Anwita將有權就AWT008計劃的開發里程碑中收取合共最高6,450萬美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account